SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-039556
Filing Date
2024-10-04
Accepted
2024-10-04 17:02:48
Documents
18
Period of Report
2024-09-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45887
2 ex16-1.htm EX-16.1 6192
3 ex16-1_001.jpg GRAPHIC 505853
4 ex16-1_002.jpg GRAPHIC 102871
5 ex16-1_003.jpg GRAPHIC 949714
  Complete submission text file 0001493152-24-039556.txt   2374926

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tnfa-20240930.xsd EX-101.SCH 3018
7 XBRL LABEL FILE tnfa-20240930_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE tnfa-20240930_pre.xml EX-101.PRE 24167
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3697
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241355548
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)